Evaluation of enhanced condensational growth (ECG) for controlled respiratory drug delivery in a mouth-throat and upper tracheobronchial model.
OBJECTIVE
The objective of this study is to evaluate the effects of enhanced condensational growth (ECG), as a novel inhalation drug delivery method, on nano-aerosol deposition in a mouth-throat (MT) and upper tracheobronchial (TB) model using in vitro experiments and computational fluid dynamics (CFD) simulations.


METHODS
Separate streams of nebulized nano-aerosols and saturated humidified air (39 degrees C-ECG; 25 degrees C-control) were combined as they were introduced into a realistic MT-TB geometry. Aerosol deposition was determined in the MT, generations G0-G2 (trachea-lobar bronchi) and G3-G5 and compared to CFD simulations.


RESULTS
Using ECG conditions, deposition of 560 and 900 nm aerosols was low in the MT region of the MT-TB model. Aerosol drug deposition in the G0-G2 and G3-G5 regions increased due to enhanced condensational growth compared to control. CFD-predicted depositions were generally in good agreement with the experimental values.


CONCLUSIONS
The ECG platform appears to offer an effective method of delivering nano-aerosols through the extrathoracic region, with minimal deposition, to the tracheobronchial airways and beyond. Aerosol deposition is then facilitated as enhanced condensational growth increases particle size. Future studies will investigate the effects of physio-chemical drug properties and realistic inhalation profiles on ECG growth characteristics.
Hindle
Michael
M
Department of Pharmaceutics, Virginia Commonwealth University, 410 N. 12th St., P.O. Box 980533, Richmond, Virginia 23298-0533, USA. mhindle@vcu.edu
Longest
P Worth
PW
D000280:Administration, Inhalation; D000336:Aerosols; D000420:Albuterol / Q000008:administration & dosage; D001980:Bronchi / Q000033:anatomy & histology / Q000502:physiology*; D003198:Computer Simulation; D016503:Drug Delivery Systems / Q000379:methods*; D004867:Equipment Design; D006801:Humans; D008953:Models, Anatomic; D008954:Models, Biological; D009055:Mouth / Q000033:anatomy & histology / Q000502:physiology*; D053758:Nanoparticles / Q000008:administration & dosage; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D010614:Pharynx / Q000033:anatomy & histology / Q000502:physiology*; D011237:Predictive Value of Tests; D014132:Trachea / Q000033:anatomy & histology / Q000502:physiology*
D000336:Aerosols; D000420:Albuterol
J Biomech Eng. 2008 Feb;130(1):011008
18298184
J Aerosol Med. 1998 Winter;11(4):221-9
10346665
Trends Biotechnol. 2007 Dec;25(12):563-70
17997181
J Aerosol Med. 2001 Summer;14(2):255-66
11681657
Inhal Toxicol. 2000 Aug;12(8):715-31
10880153
Med Eng Phys. 2007 Apr;29(3):350-66
16814588
J Antimicrob Chemother. 2003 Dec;52(6):981-6
14613962
Eur Respir J. 1998 Dec;12(6):1346-53
9877489
J Aerosol Med. 1995 Sep;8 Suppl 3:S21-6; discussion S27
10157895
J Aerosol Med. 2006 Summer;19(2):184-98
16796543
J Aerosol Med. 2007 Fall;20(3):227-35
17894531
J Aerosol Med. 2006 Spring;19(1):36-46
16551213
Proc Am Thorac Soc. 2004;1(4):321-8
16113453
Aerosol Sci Technol. 2010 Jun 1;44(6):473-483
20640054
J Aerosol Med. 2006 Winter;19(4):473-83
17196076
J Drug Target. 2001;9(4):295-302
11697032
J Aerosol Med Pulm Drug Deliv. 2009 Jun;22(2):67-83
18956949
Adv Drug Deliv Rev. 2008 May 22;60(8):863-75
18308418
Aerosol Sci Technol. 2003;37(8):659-671
19011693
J Appl Physiol (1985). 2008 Jun;104(6):1761-77
18388247
Am J Physiol Lung Cell Mol Physiol. 2008 Sep;295(3):L400-11
18641236
Ann Occup Hyg. 1982;26(1-4):93-108
7181315
J Appl Physiol. 1971 Aug;31(2):207-17
5558242
J Aerosol Med Pulm Drug Deliv. 2009 Jun;22(2):99-112
18956950
Bull Math Biol. 1980;42(3):461-80
7378614
J Aerosol Sci. 2010 Aug 1;41(8):805-820
20835406
Respir Med. 2004 Apr;98 Suppl A:S17-21
15139564
Ann Biomed Eng. 2007 Apr;35(4):560-81
17237991
Int J Pharm. 2009 Jun 22;375(1-2):114-22
19481697